Skip to main content
SpringerLink
Log in
Book cover

Infectious Causes of Cancer pp 113–127Cite as

Hodgkin’s Disease

  • Chapter

  • 229 Accesses

Part of the book series: Infectious Disease ((ID))

Abstract

Sir Thomas Hodgkin first described Hodgkin’s disease (HD) in 1832 as a physician in training This was followed by the description of the Hodgkin and Reed–Sternberg cells by multiple researchers between 1878 and 1902. The Lukes & Butler, Rye, and REAL classifications of HD were devised in the 1960s, 1980s, and 1990s, respectively. Yet, despite our longstanding ability to identify HD, the etiology of the disease has remained obscure.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. MacMahon B. Epidemiology of Hodgkin’s disease. Cancer Res 1966; 26: 1189–1200.

    PubMed  CAS  Google Scholar 

  2. Grufferman S, Delzell E. Epidemiology of Hodgkin’s disease. Epidemiol Rev 1984; 6: 76–106.

    PubMed  CAS  Google Scholar 

  3. De Vita VT, Jr, Mauch PM, Harris NE Hodgkin’s disease. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. Philadelphia, New York: Lippincott-Raven, 1997, pp. 2242–2283.

    Google Scholar 

  4. Armstrong AA, Alexander FE, Cartwright R, et al. Epstein-Barr virus and Hodgkin’s disease: further evidence for the three disease hypothesis. Leukemia 1998; 12: 1272–1276.

    Article  PubMed  CAS  Google Scholar 

  5. Cole P, MacMahon B, Aisenberg A. Mortality from Hodgkin’s disease in the United States. Evidence for the multiple etiology hypothesis. Lancet 1968; 11: 1371–1376.

    Article  Google Scholar 

  6. Vianna NJ, Greenwald P, Davies JNP. Nature of Hodgkin’s disease agent. Lancet 1971; 1: 733–736.

    Article  PubMed  CAS  Google Scholar 

  7. Gutensohn N, Cole P. Childhood and social environment and Hodgkin’s disease. N Engl J Medi 1981; 304: 135–140.

    Article  CAS  Google Scholar 

  8. Mueller N, Evans A, Harris NL, et al. Hodgkin’s disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989; 320: 689–695.

    Article  PubMed  CAS  Google Scholar 

  9. Kvale G, Hoiby EA, Pederson E. Hodgkin’s disease in patients with previous infectious mononucleiosis. Cancer 1979; 23: 593–597.

    CAS  Google Scholar 

  10. Rosdahl N, Larsen SO, Clemmensen J. Hodgkin’s disease in patients with previous infectious mononucleiosis: 30 years’ experience. Br Med J 1974; 2: 253–256.

    Article  PubMed  CAS  Google Scholar 

  11. Johansson B, Klein G, Henle W, Henle G. Epstein-Barr virus-associated antibody patterns in malignant lymphoma and leukemia. Hodgkin’s disease. Int Cancer 1970; 6: 450–462.

    Article  CAS  Google Scholar 

  12. Taylor GM, Gokhale DA, Crowther D, et al. Increased frequency of HLA-DPB 1 *0301 in Hodgkin’s disease suggests that susceptibility is HVR-sequence and subtype-associated. Leukemia 1996; 10: 854–859.

    PubMed  CAS  Google Scholar 

  13. Biggar RJ, Horm J, Goedert JJ, Melbye M. Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am J Epidemiol 1987; 126: 578–586.

    PubMed  CAS  Google Scholar 

  14. Hessol NA, Katz MH, Liu JY, Buchbinder SP, Rubino CJ, Holmberg SD. Increased incidence of Hodgkin’s disease in homosexual men with HIV infection. Ann Intern Med 1992; 117: 309–311.

    PubMed  CAS  Google Scholar 

  15. Lyter DW, Bryant J, Thackeray R, Rinaldo CR, Kingsley LA. Incidence of human immunodeficiency virus-related and nonrelated malignancies in a large cohort of homosexual men. J Clin Oncol 1995; 13: 2540–2546.

    PubMed  CAS  Google Scholar 

  16. Rabkin CS, Biggar RJ, Horm JW. Increasing incidence of cancers associated with human immunodeficiency virus epidemic. Int J Cancer 1991; 47: 692–696.

    Article  PubMed  CAS  Google Scholar 

  17. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351: 1833–1839.

    Article  PubMed  CAS  Google Scholar 

  18. Grulich A, Wan X, Law M, Coates M, Kaldor J. Rates of non-AIDS defining cancers in people with AIDS. J AIDS Hum Retrovirol 1997; 14: A18.

    Google Scholar 

  19. Andrieu JM, Roithmann S, Burarie JM, et al. Hodgkin’s disease during HIV-1 infection: The French Registry experience. French Registry of HIV Associated Tumors. Ann Oncol 1993; 4: 635–641.

    PubMed  CAS  Google Scholar 

  20. Monfardini S, Tirelli U, Vaccher E, Foa R, Gavosta F. Hodgkin’s disease in 63 intravenous drug users infected with human immunodeficiency virus. Ann Oncol 1991; 2: 201–205.

    Article  PubMed  Google Scholar 

  21. Rubio R. Hodgkin’s disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative Study Group of Malignancies Associated with HIV Infection of Madrid. Cancer 1994; 73: 2400–2407.

    Article  PubMed  CAS  Google Scholar 

  22. Herbst H, Stein H, Niedobitek G. Epstein-Barr virus and CD 30+ malignant lymphomas. Crit Rev Oncol 1993; 4: 191–239.

    CAS  Google Scholar 

  23. Gruss H, Pinto A, Duyster J, Poppema S, Herrmann F. Hodgkin’s disease: a tumor with disturbed immunological pathways. Immunol Today 1997; 18: 156–163.

    Article  PubMed  CAS  Google Scholar 

  24. Cossman J, Messineo C, Bagg A. Reed-Sternberg cell: survival in a hostile sea. Lab Invest 1998; 78: 229–235.

    PubMed  CAS  Google Scholar 

  25. Niedobitek G. The role of Epstein-Barr virus in the pathogenesis of Hodgkin’s disease. Ann Oncol 1996; 7: 5–10.

    Article  Google Scholar 

  26. Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin’s and Reed-Sternberg cells. Am J Pathol 1991; 130: 701–708.

    Google Scholar 

  27. Poppema S, de Jong B, Atmosoerodjo J, Idenberg V, Visser L, de Ley L. Morphologic, immunologic, enzyme histochemical and chromosomal analysis of a cell line derived from Hodgkin’s disease. Evidence for a B-cell origin of Sternberg-Reed cells. Cancer 1985; 55: 683–690.

    Article  PubMed  CAS  Google Scholar 

  28. Mason DY, Banks PM, Chan J. Nodular lymphocyte predominance in Hodgkin’s disease. A distinct clinicopathological entity. Am J Surg Pathol 1994; 18: 526–530.

    Article  PubMed  CAS  Google Scholar 

  29. Stein H, Hummel M, Marafioti T, Anagnostopoulos I, Foss HD. Molecular biology of Hodgkin’s disease. Cancer Sury 1997; 30: 107–123.

    CAS  Google Scholar 

  30. Weiss LM, Strickler JG, Hu E, Warnke RA, Sklar J. Immunoglobulin gene rearrangements in Hodgkin’s disease. Hum Pathol 1986; 17: 1009–1014.

    Article  PubMed  CAS  Google Scholar 

  31. Knowles DM, Neri A, Pelicci PG. Immunoglobulin and T-cell receptor beta-chain gene rearrangement analysis of Hodgkin’s disease: implications for lineage determination and differential diagnosis. Proc Nat Acad Sci USA 1986; 83: 7942–7946.

    Article  PubMed  CAS  Google Scholar 

  32. Kuppers R, Zhao M, Hansmann ML, Rajewsky K. Tracing B-cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J 1993; 12: 4955–4967.

    PubMed  CAS  Google Scholar 

  33. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin’s disease: Hodgkin and Reed-Sternberg cells picked from histologic sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Nat Acad Sci USA 1994; 91: 10962–10966.

    Article  PubMed  CAS  Google Scholar 

  34. Atkin NB. Cytogenetics of Hodgkin’s disease. Cytogenet Cell Genet 1998; 80: 23–27.

    Article  PubMed  CAS  Google Scholar 

  35. Gruss HJ, Kadin ME. Pathophysiology of Hodgkin’s disease: functional and molecular aspects. Bailléres Clin Hematol 1996; 9: 417–446.

    Article  CAS  Google Scholar 

  36. Stuart AE, Williams ARW, Habeshaw JA. Rosetting and other reactions of the Reed-Sternberg cell. J Pathol 1976; 122: 81–90.

    Article  Google Scholar 

  37. Gruss HG, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85: 3378–3404.

    PubMed  CAS  Google Scholar 

  38. Eltringham JR, Kaplan HS. Impaired delayed-hypersensitivity responses in 154 patients with untreated Hodgkin’s disease. J Natl Cancer Inst Monogr 1973; 36: 107–115.

    CAS  Google Scholar 

  39. Kumar RK, Penny R. Cell mediated immune deficiency in Hodgkin’s disease. Immunol Today 1982; 3: 269–273.

    Article  Google Scholar 

  40. Dolcetti R, Boiocchi M. Epstein-Barr virus in the pathogenesis of Hodgkin’s disease. Biomed Pharmacother 1998; 52: 13–25.

    Article  PubMed  CAS  Google Scholar 

  41. Levine AM. Hodgkin’s disease in the setting of human immunodeficiency virus infection. J Nat Cancer Inst Monogr 1998; 23: 37–42.

    Article  Google Scholar 

  42. Serrano M, Bellas C, Campo E, et al. Hodgkin’s disease in patients with antibodies to human immunodeficiency virus. A study of 22 patients. Cancer 1990; 65: 2248–2254.

    Article  PubMed  CAS  Google Scholar 

  43. Uccini S, Monardo F, Stoppacciaro A, et al. High frequency of Epstein-Barr virus genome in Hodgkin’s disease of HIV-positive patients. Int J Cancer 1990; 46: 581–585.

    Article  PubMed  CAS  Google Scholar 

  44. Kieff E. Current perspectives on the molecular pathogenesis of virus-induced cancers in human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst Monogr 1998; 23: 7–14.

    Article  PubMed  CAS  Google Scholar 

  45. Cohen J. Epstein-Barr virus infections, including infectious mononucleiosis. In: Fauci AS, Braunwald E, Isselbacher KJ, et al. (eds). Harrison’s Principles of Internal Medicine. New York: McGraw-Hill, 1998, pp. 1089–1091.

    Google Scholar 

  46. Howe JG, Steitz JA. Localization of Epstein-Barr virus-encoded small RNA’s by in situ hybridization. Proc Natl Acad Sci USA 1986; 83: 9006–9010.

    Article  PubMed  CAS  Google Scholar 

  47. Wang D, Liebowitz D, Kieff ED. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43: 831–840.

    Article  PubMed  CAS  Google Scholar 

  48. Mosialos G, Birkenbach M, Yalammanchii R, Van Arsdale T, Ware C, Kieff ED. The Epstein-Barr virus latent membrane protein-1 (LMP-1) engages signalling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389–399.

    Article  PubMed  CAS  Google Scholar 

  49. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP-1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domains. Oncogene 1995; 10: 549–560.

    PubMed  CAS  Google Scholar 

  50. Johannsen E, Miller CL, Grossman SR, Kieff ED. EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes. J Virol 1997; 70: 4179–4183.

    Google Scholar 

  51. Pear WS, Aster JC, Scott ML, et al. Exclusive development of T-cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996; 183: 2283–2291.

    Article  PubMed  CAS  Google Scholar 

  52. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998; 338: 1413–1421.

    Article  PubMed  CAS  Google Scholar 

  53. Kieff ED. Epstein-Barr virus and its replication. In: Fields B, Knipe D, Howley PM (eds). Field’s Virology. Philadelphia: Lippincott-Raven, 1996, pp. 2343–2396.

    Google Scholar 

  54. Niedobitek G, Young LS, Herbst H. Epstein-Barr virus infection and the pathogenesis of malignant lymphomas. Cancer Sury 1997; 30: 143–162.

    CAS  Google Scholar 

  55. Kube D, Vockerodt M, Weber O, et al. Expression of Epstein-Barr virus nuclear antigen-1 is associated with enhanced expression of CD 25 in the Hodgkin cell line L428. J Virol 1999; 73: 1630–1636.

    PubMed  CAS  Google Scholar 

  56. Khanna R, Burrows SR, Kurilla MG, et al. Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992; 176: 169.

    Article  PubMed  CAS  Google Scholar 

  57. Oudejans JJ, Jiwa NM, Kummer JA, et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin’s disease. Blood 1996; 87: 3844–3851.

    PubMed  CAS  Google Scholar 

  58. Sculley TB, Apollini A, Hurren L, Moss DJ, Cooper DA. Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis 1990; 162: 643–648.

    Article  PubMed  CAS  Google Scholar 

  59. Walling DM, Edmistan SN, Sixbey JW, Abdel-Hamid M, Resnick L, Raab-Traub N. Co-infection of multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia. Proc Natl Acad Sci USA 1992; 89: 6560–6564.

    Article  PubMed  CAS  Google Scholar 

  60. Kyaw MT, Hurren L, Evans L, et al. Expression of B-type Epstein-Barr virus in HIV-infected patients and cardiac transplant recipients. AIDS Res Hum Retroviruses 1992; 8: 1869–1874.

    Article  PubMed  CAS  Google Scholar 

  61. Yao QY, Croom-Carter DSG, Tierney RJ, et al. Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophiliac cohort. J Virol 1998; 77: 4352–4363.

    Google Scholar 

  62. SEER cancer statistics review, 1973–1991: tables and graphs. In: Ries LA, Miller BA, Hankey BF, Kosary CL, Harms A, Edwards BK (eds). Bethesda: National Institutes of Health, National Cancer Institute, 1994.

    Google Scholar 

  63. Spring SB, Hascall G, Gruber J. Issues related to the development of Epstein-Barr virus vaccines. J Natl Cancer Inst 1996; 88: 1436–1441.

    Article  PubMed  CAS  Google Scholar 

  64. Gu SY, Huang TM, Ruan L, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. In: Tursz T, Pagano JS, Ablashi DV, de The G, Lenoir G, Pearson GR (eds). The Epstein-Barr virus and associated diseases. Montrouge, France: Colloque INSERM John Libbey: Eurotext, 1993, pp. 579–584.

    Google Scholar 

  65. Moss DJ, Schmidt C, Elliott S, Suhrbier A, Burrows S, Khanna R. Strategies involved in developing an effective vaccine to EBV-associated disease. Adv Cancer Res 1996; 69: 213–245.

    Article  PubMed  CAS  Google Scholar 

  66. Murray R, J., Kurilla MG, Brooks M, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBVpositive malignancies. J Exp Med 1992; 176: 157–168.

    Article  PubMed  CAS  Google Scholar 

  67. Sing AP, Ambinder RF, Hong DJ, et al. Isolation of Epstein—Barr virus (EBV)-specific cytotoxic lymphocytes that lyse Reed—Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin’s disease. Blood 1997; 89: 1978–1986.

    PubMed  CAS  Google Scholar 

  68. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based therapy. J Immunol 1997; 158: 3325–3334.

    PubMed  CAS  Google Scholar 

  69. Roskrow AM, Suzuki N, Gan YJ, et al. Epstein—Barr virus (EBV) specific cytotoxic lymphocytes for the treatments of patients with EBV-positive relapsed Hodgkin’s disease. Blood 1998; 91: 2925–2934.

    PubMed  CAS  Google Scholar 

  70. Renner C, Ohnesorge S, Held G, et al. T cells from patients with Hodgkin’s disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 1996; 88: 236–241.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Paula G. O’Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David T. Scadden
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Viral Epidemiology Branch, National Cancer Institute, 6120 Executive Blvd., Room 8012, MSC 7248, 20852, Rockville, MD, USA

    James J. Goedert MD (Chief) (Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

O’Connor, P.G., Scadden, D.T. (2000). Hodgkin’s Disease. In: Goedert, J.J. (eds) Infectious Causes of Cancer. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-024-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-024-7_7

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9621-5

  • Online ISBN: 978-1-59259-024-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation